.jpeg)
2026-08-24 07:41:38
Trelagliptin is a long-acting DPP-4 inhibitor taken orally just once a week. By prolonging the action of incretin hormones, it helps regulate blood glucose levels, offering a more convenient dosing option for adults with type 2 diabetes.
2026-08-24 07:36:03
Two neurokinin receptor antagonists—fezolinetant and elinzanetant—have been approved as non-hormonal therapies for menopausal vasomotor symptoms. Data from the 2026 NIRVANA trial further confirm elinzanetant's efficacy in improving menopause-related sleep disturbances.
2026-08-21 03:30:56
Cemiplimab is a PD-1 immune checkpoint inhibitor that restores T-cell antitumor immunity. It is FDA-approved for advanced basal cell carcinoma, cutaneous squamous cell carcinoma, and selected cases of non-small cell lung cancer.
2026-08-21 03:11:31
Nintedanib (brand name OFEV) is a multi-target tyrosine kinase inhibitor that slows the decline of lung function by blocking key profibrotic signaling pathways. It is FDA-approved for idiopathic pulmonary fibrosis (IPF), progressive fibrosing interstitial lung disease (PF-ILD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
2026-08-20 03:48:01
Capmatinib (brand name Tabrecta) is a highly selective MET tyrosine kinase inhibitor developed by Novartis, approved for adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations. This article systematically examines its positioning as a second-generation MET inhibitor with superior selectivity and intracranial activity, provides detailed adverse effect incidence data from the pivotal GEOMETRY mono-1 trial, and presents grade-based management strategies for peripheral edema, hepatotoxicity, gastrointestinal effects, and other toxicities, along with dose-modification protocols and special-population guidance to support safe and effective targeted therapy.
2026-08-20 03:28:50
Gilteritinib (brand name XOSPATA) is a highly selective oral FLT3 inhibitor developed by Astellas Pharma, approved for FLT3-mutated relapsed or refractory acute myeloid leukemia (AML). This article provides a structured overview of the drug's development and manufacturing background, the standard 28-day dosing cycle, individualized treatment duration decisions, efficacy assessment milestones, dose-modification and interruption protocols, and practical daily-life management guidance to help patients and families plan treatment schedules and follow-up visits effectively.
2026-08-20 03:12:46
Dabrafenib (brand name TAFINLAR) is a highly selective oral BRAF kinase inhibitor, most commonly used in combination with the MEK inhibitor trametinib for the treatment of BRAF V600–mutant solid tumors including melanoma, non-small cell lung cancer, anaplastic thyroid cancer, and pediatric low-grade glioma. This article provides a structured overview of its approved indications, the characteristic pyrexia syndrome and other adverse effects, grade-based management strategies, dose-reduction and discontinuation protocols, and special-population safety considerations to support comprehensive treatment management.
2026-08-20 03:03:58
Adagrasib (brand name Krazati) is the second approved highly selective, covalent KRAS G12C inhibitor for patients with KRAS G12C–mutant non-small cell lung cancer and colorectal cancer. This article systematically reviews the drug's adverse-effect profile—centered on gastrointestinal toxicity and hepatotoxicity—and provides structured, grade-based management strategies for diarrhea, liver enzyme elevation, fatigue, QTc prolongation, and hematologic effects, along with dose-modification principles to help patients and clinical teams maintain the optimal balance between efficacy and safety throughout treatment.
2026-08-20 02:55:43
Tepotinib (brand name TEPMETKO) is a highly selective oral MET tyrosine kinase inhibitor approved for adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations. This article provides a structured guide to the standard dosing regimen, proactive management of peripheral edema and other adverse effects, dose-reduction and discontinuation criteria, risk assessment in special populations, drug-interaction considerations, and a recommended monitoring schedule to support safe and effective targeted therapy.
2026-08-20 02:49:09
Valganciclovir (brand name Valcyte) is the cornerstone oral antiviral agent for the prevention and treatment of cytomegalovirus (CMV) infection following solid organ transplantation. This article provides a structured overview of prophylactic regimens across kidney, heart, and kidney-pancreas transplantation, monitoring and management of myelosuppression, renal function–guided dose adjustments, strategies for addressing antiviral resistance, and practical tips for long-term adherence.
2026-08-19 06:59:25
Tivozanib is an oral VEGFR tyrosine kinase inhibitor used in advanced renal cell carcinoma, administered at 1.34 mg once daily in a 21-days-on, 7-days-off, 28-day cycle. This article covers standard dosing, dose modification for adverse events, and reduced dosing for moderate hepatic impairment.
2026-08-19 06:01:50
Anagrelide (Anagrelide) is a platelet-reducing agent widely used in essential thrombocythemia. Prolonged use may involve cardiovascular, gastrointestinal, and neurological adverse effects. This article provides a systematic overview of its safety profile and key points for long-term medication management.
